logo-loader
viewVolitionRx

VolitionRx Limited's triage test results validated in prospective trial

VolitionRx has presented data at the World Congress of GI Endoscopy 2017 conference in Hyderabad, India, from a study that confirms prior test results that the Nu.QTM Colorectal Cancer Screening Triage test reduces the total number of colonoscopy referrals while maintaining high sensitivity for cancer detection

rsz_shutterstock_181358063.jpg
Study supports earlier positive findings for Nu.QTM Colorectal Cancer Screening

VolitionRx Limited (NYSEMKT:VNRX) has presented data at the World Congress of GI Endoscopy 2017 conference in Hyderabad, India, from a study that confirms prior test results that the Nu.QTM Colorectal Cancer Screening Triage test reduces the total number of colonoscopy referrals while maintaining high sensitivity for cancer detection.

"This is a key clinical milestone in the launch of our Nu.QTM Triage product. This validation study, in a second population of 1,961 subjects, greatly assists us with sales and marketing efforts in the EU and Asia," said Louise Day, Chief Marketing and Communications Officer at VolitionRx.

The lead author of the study, Dr. Marielle Herzog, commented, "This data confirms the role that the Nu.QTM Triage test can play in accelerating the diagnosis of colorectal cancer."

Quick facts: VolitionRx

Price: 4.28 USD

NYSEMKT:VNRX
Market: NYSEMKT
Market Cap: $175.88 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

VolitionRx CEO discusses 'spectacular' results from Nu.Q proof of concept study

VolitionRx Limited's (NYSEAMERICAN:VNRX) Cameron Reynolds discusses with Proactive London's Andrew Scott the results from the latest proof of concept study on its Nu.Q cancer-test assay. He says the finding's have revealed an impressive ability to detect with accuracy non-Hodgkins lymphoma...

1 day, 17 hours ago

2 min read